I'm not sure if the following article from December 2023 has already been mentioned in this thread: https://doi.org/10.1016/j.ejmech.2023.115827
The article has the following line: "However, the development and clinical use of Bisantrene have faced several challenges. One major problem is its cardiotoxicity, which is a common side effect of anthracycline-based chemotherapy. Bisantrene has shown a higher incidence of cardiotoxicity compared to other anthracyclines, limiting its clinical application."
From where would the authors have gathered this information? Is there a reference we can check to determine the validity of their claims? @RaceOncology - could you please comment on this?
Cardioprotection thread, page-733
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |